The COVID-19 vaccine developed by Gamaleya Research institute and Russian defense ministry is set to get registered by August 12, 2020, as confirmed by Health Deputy minister Oleg Gridnev. The number of Covid-19 cases currently stands at 19,854,583 with the U.S and Brazil having the grim distinction of having most cases.
As the number of cases spikes, Russia is all set to register its indigenous vaccine that the country has been pushing for extensively. As reported by live mint, the volunteers on whom the vaccine was administered showed a positive immune response. Phase I trials for the vaccine began on June 18 and included 38 volunteers. All participants showed a positive response and were released on July 15 and July 20. Alexander Gintsburg, director of the Gamaleya National Research Centre, said that there were no concerns that the vaccine could cause harm to a person’s health.
The World Health Organization (WHO) has urged the Russian government to follow established standards and protocols to produce a safe vaccine and that all vaccines will go through full stages of testing before being rolled out for mass production. This comes after Moscow has been pushing aggressively to roll out the Covid-19 vaccine swiftly.
Dr. Anthony Fauci, World-renowned US infectious disease specialist raised concerns over the fast-track approach of producing a COVID-19 vaccine. I do hope that the Chinese and the Russians are actually testing a vaccine before they are administering the vaccine to anyone because claims of having a vaccine ready to distribute before you do testing I think is problematic at best,” he said.
Many vaccine candidates are in different stages of Human trials as the World is racing to produce a vaccine against the novel coronavirus. There are different stages of trials associated with a vaccine being tested. Preclinical trials; where vaccines are administered on animals to see if they induce an immune response. Phase I trials; where vaccines are given to small numbers of people to test dosage and safety. Phase II trials; where it is administered to a large number of volunteers from different age demographics to see if it behaves differently. In phase III; it is administered to thousands of people to determine the efficacy of a vaccine.